Ashton Thomas Private Wealth LLC Takes Position in Ventyx Biosciences, Inc. $VTYX

Ashton Thomas Private Wealth LLC bought a new stake in shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 33,374 shares of the company’s stock, valued at approximately $71,000.

Several other large investors have also recently modified their holdings of the stock. CWM LLC increased its position in shares of Ventyx Biosciences by 7.6% during the 2nd quarter. CWM LLC now owns 57,145 shares of the company’s stock valued at $122,000 after purchasing an additional 4,057 shares during the last quarter. Vanguard Personalized Indexing Management LLC increased its position in shares of Ventyx Biosciences by 104.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 46,711 shares of the company’s stock valued at $100,000 after purchasing an additional 23,828 shares during the last quarter. Wealth Enhancement Advisory Services LLC increased its position in shares of Ventyx Biosciences by 21.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 29,657 shares of the company’s stock valued at $62,000 after purchasing an additional 5,174 shares during the last quarter. Pallas Capital Advisors LLC bought a new position in shares of Ventyx Biosciences during the 2nd quarter valued at approximately $38,000. Finally, Acadian Asset Management LLC increased its position in shares of Ventyx Biosciences by 443.8% during the 1st quarter. Acadian Asset Management LLC now owns 537,054 shares of the company’s stock valued at $614,000 after purchasing an additional 438,286 shares during the last quarter. Institutional investors own 97.88% of the company’s stock.

Ventyx Biosciences Trading Up 1.3%

VTYX opened at $8.53 on Friday. Ventyx Biosciences, Inc. has a 12-month low of $0.78 and a 12-month high of $9.50. The business’s fifty day simple moving average is $3.59 and its 200-day simple moving average is $2.65. The company has a market capitalization of $608.27 million, a price-to-earnings ratio of -5.08 and a beta of 1.01.

Ventyx Biosciences (NASDAQ:VTYX) last posted its quarterly earnings results on Thursday, August 7th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.07. On average, equities research analysts predict that Ventyx Biosciences, Inc. will post -2.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on VTYX. Oppenheimer boosted their target price on Ventyx Biosciences from $9.00 to $14.00 and gave the company an “outperform” rating in a research report on Monday, October 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ventyx Biosciences in a research report on Wednesday, October 8th. Finally, Wall Street Zen raised Ventyx Biosciences from a “sell” rating to a “hold” rating in a research report on Saturday, August 9th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $10.00.

Ventyx Biosciences Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.